No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer.

Masatoshi Tanaka Takahiro KimuraYumina IwamuraYuki EneiYuya IwamotoYu ImaiYuzo InabaAkihiro MatsukawaHajime OnumaKagenori Ito Keiichiro MoriHiroshi SasakiJun MikiAkira FurutaKenta MikiShin Egawa

Published in: The Prostate (2019)

The results of this study failed to show the survival benefit of extended use of DOC over 10 cycles in CRPC patients in the era of innovative drugs such as abiraterone acetate, enzalutamide, and cabazitaxel. Further prospective studies are required to confirm our findings.

Keyphrases

end stage renal disease
prostate cancer
chronic kidney disease
ejection fraction
prognostic factors
peritoneal dialysis
squamous cell carcinoma
radiation therapy
patient reported outcomes
case control
combination therapy
replacement therapy
smoking cessation